- Home
- CYCC vs ASRT Comparison
CYCC vs ASRT Comparison
Compare CYCC & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- ASRT
- Stock Information
- Founded
- CYCC 1992
- ASRT 1995
- Country
- CYCC Malaysia
- ASRT United States
- Employees
- CYCC N/A
- ASRT N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- ASRT Health Care
- Exchange
- CYCC Nasdaq
- ASRT Nasdaq
- Market Cap
- CYCC 61.2M
- ASRT 57.9M
- IPO Year
- CYCC N/A
- ASRT 1997
- Fundamental
- Price
- CYCC $1.63
- ASRT $0.66
- Analyst Decision
- CYCC
- ASRT Strong Buy
- Analyst Count
- CYCC 0
- ASRT 3
- Target Price
- CYCC N/A
- ASRT $3.08
- AVG Volume (30 Days)
- CYCC 191.0K
- ASRT 284.6K
- Earning Date
- CYCC 05-15-2025
- ASRT 05-12-2025
- Dividend Yield
- CYCC 147.24%
- ASRT N/A
- EPS Growth
- CYCC N/A
- ASRT N/A
- EPS
- CYCC N/A
- ASRT N/A
- Revenue
- CYCC $14,000.00
- ASRT $119,001,000.00
- Revenue This Year
- CYCC $137.21
- ASRT N/A
- Revenue Next Year
- CYCC N/A
- ASRT $11.71
- P/E Ratio
- CYCC N/A
- ASRT N/A
- Revenue Growth
- CYCC N/A
- ASRT N/A
- 52 Week Low
- CYCC $1.36
- ASRT $0.51
- 52 Week High
- CYCC $49.34
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- ASRT 50.57
- Support Level
- CYCC $1.36
- ASRT $0.67
- Resistance Level
- CYCC $1.94
- ASRT $0.71
- Average True Range (ATR)
- CYCC 0.43
- ASRT 0.04
- MACD
- CYCC -0.07
- ASRT 0.00
- Stochastic Oscillator
- CYCC 8.31
- ASRT 52.69
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.